Renal Cluster Drug Development Pipeline Review, 2017

  • ID: 4258952
  • Report
  • Region: Global
  • 181 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • A1M Pharma AB
  • Bayer AG
  • DURECT Corp
  • Horizon Pharma Plc
  • Opsona Therapeutics Ltd
  • Shire Plc
  • MORE

Renal Cluster Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the renal cluster pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Kidney Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Acute Renal Failure (ARF), Kidney Transplant Rejection, and also features dormant and discontinued projects.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. There are a total of 39 products in development for this indication, by 28 companies and five academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Pharmaxis, Cellmid and Vascular Biogenics.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. There are a total of 59 products in development for this indication, by 48 companies and two academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Apceth Biopharma, AstraZeneca, Bayer, Evotec, Novartis, Sarfez Pharmaceuticals and Vidasym.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. There are a total of 36 products in development for this indication, by 34 companies and one academic institution. A number of companies are operating in this space, with A1M Pharma alone developing multiple programs within the area.

Finally, kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Due to differences between the two patients, an autoimmune reaction against the donor kidney may occur in the recipient. There are a total of 39 products in development for this indication, by 33 companies and two academic institutions. Key companies operating in this pipeline space include Astellas Pharma, GlaxoSmithKline, Hillhurst Biopharmaceuticals and Kyowa Hakko Kirin.

While kidney transplant rejection treatments are largely focused on immune system molecular targets such as tumor necrosis factor alpha and complement factors, a range of cellular signaling components are being pursued in the other three key indications, including the activin receptors, cyclin dependent kinases, and growth factor receptors.

Scope

  • Which companies are the most active within the pipeline for renal cluster therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of renal cluster therapeutics?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • A1M Pharma AB
  • Bayer AG
  • DURECT Corp
  • Horizon Pharma Plc
  • Opsona Therapeutics Ltd
  • Shire Plc
  • MORE

1. Report Guidance

2. Executive Summary

3. Introduction

4. Report Coverage

  • Kidney Fibrosis - Overview
  • Chronic Kidney Disease (Chronic Renal Failure) - Overview
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview
  • Kidney Transplant Rejection - Overview

5. Therapeutics Development

  • Kidney Fibrosis
  • Chronic Kidney Disease (Chronic Renal Failure)
  • Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Kidney Transplant Rejection

6. Therapeutics Assessment

  • Kidney Fibrosis
  • Chronic Kidney Disease (Chronic Renal Failure)
  • Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Kidney Transplant Rejection

7. Companies Involved in Therapeutics Development

  • Kidney Fibrosis
  • Chronic Kidney Disease (Chronic Renal Failure)
  • Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Kidney Transplant Rejection

8. Dormant Projects

  • Kidney Fibrosis
  • Chronic Kidney Disease (Chronic Renal Failure)
  • Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Kidney Transplant Rejection

9. Discontinued Products

  • Chronic Kidney Disease (Chronic Renal Failure)
  • Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Kidney Transplant Rejection

10. Product Development Milestones

  • Kidney Fibrosis
  • Chronic Kidney Disease (Chronic Renal Failure)
  • Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Kidney Transplant Rejection

11. Appendix

  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation

List of Tables

  • Number of Products under Development for Kidney Fibrosis
  • Number of Products under Development by Companies, Kidney Fibrosis
  • Number of Products under Development by Universities/Institutes, Kidney Fibrosis
  • Products under Development by Companies, Kidney Fibrosis
  • Products under Development by Universities/Institutes, Kidney Fibrosis
  • Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure)
  • Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure)
  • Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products under Development by Companies, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products under Development by Universities/Institutes, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Products under Development by Companies, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Products under Development by Universities/Institutes, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products under Development for Kidney Transplant Rejection
  • Number of Products under Development by Companies, Kidney Transplant Rejection
  • Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection
  • Products under Development by Companies, Kidney Transplant Rejection
  • Products under Development by Universities/Institutes, Kidney Transplant Rejection
  • Number of Products by Stage and Target, Kidney Fibrosis
  • Number of Products by Stage and Mechanism of Action, Kidney Fibrosis
  • Number of Products by Stage and Route of Administration, Kidney Fibrosis
  • Number of Products by Stage and Molecule Type, Kidney Fibrosis
  • Number of Products by Stage and Target, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products by Stage and Mechanism of Action, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products by Stage and Route of Administration, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products by Stage and Molecule Type, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products by Stage and Target, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products by Stage and Mechanism of Action, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products by Stage and Route of Administration, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products by Stage and Molecule Type, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products by Stage and Target, Kidney Transplant Rejection
  • Number of Products by Stage and Mechanism of Action, Kidney Transplant Rejection
  • Number of Products by Stage and Route of Administration, Kidney Transplant Rejection
  • Number of Products by Stage and Molecule Type, Kidney Transplant Rejection
  • Kidney Fibrosis - Pipeline by AbbVie Inc
  • Kidney Fibrosis - Pipeline by Allergan Plc
  • Kidney Fibrosis - Pipeline by Angion Biomedica Corp
  • Kidney Fibrosis - Pipeline by Apollo Endosurgery Inc
  • Kidney Fibrosis - Pipeline by BiOrion Technologies BV
  • Kidney Fibrosis - Pipeline by Cellmid Ltd
  • Kidney Fibrosis - Pipeline by Epigen Biosciences Inc
  • Kidney Fibrosis - Pipeline by Evotec AG
  • Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc
  • Kidney Fibrosis - Pipeline by GenKyoTex SA
  • Kidney Fibrosis - Pipeline by Horizon Pharma Plc
  • Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals Inc
  • Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH
  • Kidney Fibrosis - Pipeline by MorphoSys AG
  • Kidney Fibrosis - Pipeline by Pharmaxis Ltd
  • Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc
  • Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc
  • Kidney Fibrosis - Pipeline by Sirnaomics Inc
  • Kidney Fibrosis - Pipeline by Symic Biomedical Inc
  • Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BLR Bio LLC
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Chugai Pharmaceutical Co Ltd
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Complexa Inc
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Corp
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by CTI BioPharma Corp
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by F. Hoffmann-La Roche Ltd
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gilead Sciences Inc
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lupin Ltd
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Navya Biologicals Pvt Ltd
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co Ltd
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co Ltd
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prismic Pharmaceuticals Inc
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals LLC
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals Inc
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Regulus Therapeutics Inc
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Relypsa Inc
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Spotlight Innovation Inc
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Taisho Pharmaceutical Co Ltd
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries Inc
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Tricida Inc
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unity Biotechnology Inc
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vascular BioSciences
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VESSL Therapeutics Ltd
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Alloksys Life Sciences BV
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma BV
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Atox Bio Ltd
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Ltd
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa Inc
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Therapeutics Inc
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corp
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Evotec AG
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Exponential Biotherapies Inc
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics Inc
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma Inc
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitotech SA
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex Inc
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeuroVive Pharmaceutical AB
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Nyken BV
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ProMetic Life Sciences Inc
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals Inc
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Rediscovery Life Sciences
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Regulus Therapeutics Inc
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co Ltd
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed SL
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics Inc
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Stealth BioTherapeutics Inc
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos Therapeutics Inc
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Ltd
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Xigen SA
  • Kidney Transplant Rejection - Pipeline by Amgen Inc
  • Kidney Transplant Rejection - Pipeline by Angion Biomedica Corp
  • Kidney Transplant Rejection - Pipeline by Apellis Pharmaceuticals Inc
  • Kidney Transplant Rejection - Pipeline by Astellas Pharma Inc
  • Kidney Transplant Rejection - Pipeline by Biogen Inc
  • Kidney Transplant Rejection - Pipeline by Catalyst Biosciences Inc
  • Kidney Transplant Rejection - Pipeline by Corline Biomedical AB
  • Kidney Transplant Rejection - Pipeline by CSL Ltd
  • Kidney Transplant Rejection - Pipeline by GlaxoSmithKline Plc
  • Kidney Transplant Rejection - Pipeline by Grifols SA
  • Kidney Transplant Rejection - Pipeline by Hansa Medical AB
  • Kidney Transplant Rejection - Pipeline by Kyowa Hakko Kirin Co Ltd
  • Kidney Transplant Rejection - Pipeline by Magnus Life Ltd
  • Kidney Transplant Rejection - Pipeline by Noorik Biopharmaceuticals AG
  • Kidney Transplant Rejection - Pipeline by Novartis AG
  • Kidney Transplant Rejection - Pipeline by Opsona Therapeutics Ltd
  • Kidney Transplant Rejection - Pipeline by OSE Immunotherapeutics
  • Kidney Transplant Rejection - Pipeline by Pharmicell Co Ltd
  • Kidney Transplant Rejection - Pipeline by Pharming Group NV
  • Kidney Transplant Rejection - Pipeline by Prolong Pharmaceuticals LLC
  • Kidney Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc
  • Kidney Transplant Rejection - Pipeline by Shire Plc
  • Kidney Transplant Rejection - Pipeline by Tiziana Life Sciences Plc
  • Kidney Fibrosis - Dormant Projects
  • Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects
  • Kidney Transplant Rejection - Dormant Projects
  • Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products
  • Kidney Transplant Rejection - Discontinued Products

List of Figures

  • Number of Products under Development for Kidney Fibrosis
  • Number of Products under Development by Companies, Kidney Fibrosis
  • Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products under Development by Companies, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products under Development for Kidney Transplant Rejection
  • Number of Products under Development by Companies, Kidney Transplant Rejection
  • Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection
  • Number of Products by Top 10 Targets, Kidney Fibrosis
  • Number of Products by Stage and Top 10 Targets, Kidney Fibrosis
  • Number of Products by Top 10 Mechanism of Actions, Kidney Fibrosis
  • Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Fibrosis
  • Number of Products by Routes of Administration, Kidney Fibrosis
  • Number of Products by Stage and Routes of Administration, Kidney Fibrosis
  • Number of Products by Molecule Types, Kidney Fibrosis
  • Number of Products by Stage and Molecule Types, Kidney Fibrosis
  • Number of Products by Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products by Stage and Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products by Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products by Top 10 Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products by Stage and Top 10 Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products by Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products by Stage and Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure)
  • Number of Products by Top 10 Targets, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products by Stage and Top 10 Targets, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products by Top 10 Mechanism of Actions, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products by Stage and Top 10 Mechanism of Actions, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products by Routes of Administration, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products by Stage and Routes of Administration, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products by Molecule Types, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products by Stage and Molecule Types, Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Number of Products by Top 10 Targets, Kidney Transplant Rejection
  • Number of Products by Stage and Top 10 Targets, Kidney Transplant Rejection
  • Number of Products by Top 10 Mechanism of Actions, Kidney Transplant Rejection
  • Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Transplant Rejection
  • Number of Products by Routes of Administration, Kidney Transplant Rejection
  • Number of Products by Stage and Routes of Administration, Kidney Transplant Rejection
  • Number of Products by Top 10 Molecule Types, Kidney Transplant Rejection
  • Number of Products by Stage and Top 10 Molecule Types, Kidney Transplant Rejection
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • A1M Pharma AB
  • AbbVie Inc
  • Allergan Plc
  • Alloksys Life Sciences BV
  • Am-Pharma BV
  • Amgen Inc
  • Angion Biomedica Corp
  • Apceth Biopharma GmbH
  • Apellis Pharmaceuticals Inc
  • Apollo Endosurgery Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Atox Bio Ltd
  • BLR Bio LLC
  • Bayer AG
  • BiOrion Technologies BV
  • Biogen Inc
  • Boehringer Ingelheim GmbH
  • Boryung Pharmaceutical Co Ltd
  • CSL Ltd
  • CTI BioPharma Corp
  • Catalyst Biosciences Inc
  • Cellmid Ltd
  • Chugai Pharmaceutical Co Ltd
  • Complexa Inc
  • Corline Biomedical AB
  • Corvidia Corp
  • DURECT Corp
  • DiaMedica Therapeutics Inc
  • Epigen Biosciences Inc
  • Evotec AG
  • Exponential Biotherapies Inc
  • F. Hoffmann-La Roche Ltd
  • G1 Therapeutics Inc
  • GNI Group Ltd
  • Galectin Therapeutics Inc
  • GenKyoTex SA
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Grifols SA
  • Hansa Medical AB
  • Horizon Pharma Plc
  • Intercept Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • Kringle Pharma Inc
  • Kyowa Hakko Kirin Co Ltd
  • Lupin Ltd
  • Magnus Life Ltd
  • Mitotech SA
  • MorphoSys AG
  • Navya Biologicals Pvt Ltd
  • NephroGenex Inc
  • NeuroVive Pharmaceutical AB
  • Nippon Zoki Pharmaceutical Co Ltd
  • Noorik Biopharmaceuticals AG
  • Novartis AG
  • Nyken BV
  • OSE Immunotherapeutics
  • Opsona Therapeutics Ltd
  • Otsuka Holdings Co Ltd
  • Pharmaxis Ltd
  • Pharmicell Co Ltd
  • Pharming Group NV
  • Prismic Pharmaceuticals Inc
  • ProMetic Life Sciences Inc
  • Prolong Pharmaceuticals LLC
  • Quark Pharmaceuticals Inc
  • Reata Pharmaceuticals Inc
  • Rediscovery Life Sciences
  • Regulus Therapeutics Inc
  • Relypsa Inc
  • Resverlogix Corp
  • SBI Pharmaceuticals Co Ltd
  • STATegics Inc
  • Shire Plc
  • Sirnaomics Inc
  • Spherium Biomed SL
  • Spotlight Innovation Inc
  • Stealth BioTherapeutics Inc
  • Symic Biomedical Inc
  • Taisho Pharmaceutical Co Ltd
  • Thrasos Therapeutics Inc
  • Tiziana Life Sciences Plc
  • Toray Industries Inc
  • Torrent Pharmaceuticals Ltd
  • Tricida Inc
  • Unity Biotechnology Inc
  • VESSL Therapeutics Ltd
  • Vascular BioSciences
  • Vascular Biogenics Ltd
  • Vicore Pharma AB
  • Xigen SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll